Association of pretransplant serum phosphorus with posttransplant outcomes

Marcelo S. Sampaio, Miklos Z. Molnar, Csaba Kovesdy, Rajnish Mehrotra, Istvan Mucsi, John J. Sim, Mahesh Krishnan, Allen R. Nissenson, Kamyar Kalantar-Zadeh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and objectives Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. Design, setting, participants, & measurements Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita). The selected 9384 primary kidney recipients were divided into five groups according to pretransplant serum phosphorus levels (mg/dl): <3.5, 3.5 to <5.5 (reference group), 5.5 to <7.5, 7.5 to <9.5, and ≥ 9.5. Unadjusted and multivariate adjusted risks for transplant outcomes were compared. Results Patients were 48±14 years old and included 37% women and 27% African Americans. After multivariate adjustment, all-cause and cardiovascular death hazard ratios were 2.44 (95% confidence interval: 1.28 to 4.65) and 3.63 (1.13 to 11.64), respectively, in recipients in the ≥9.5 group; allograft loss hazard ratios were 1.42 (1.04 to 1.95) and 2.36 (1.33 to 4.17) in recipients with 7.5 to > 9.5 and ≥ 9.5, respectively. No significant association with delayed graft function was found. Conclusions Pretransplant phosphorus levels 7.5 to > 9.5 mg/dl and ≥ 9.5 mg/dl were associated with increased risk of functional graft failure and increased risk of all-cause and cardiovascular deaths, respectively, when compared with 3.5 to < 5.5 mg/dl. Additional studies are needed to examine whether more aggressive control of pretransplant serum phosphorus may improve posttransplant outcomes.

Original languageEnglish (US)
Pages (from-to)2712-2721
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Phosphorus
Serum
Delayed Graft Function
Transplants
Kidney
Chronic Renal Insufficiency
Registries
Dialysis
Cause of Death
Cardiovascular Diseases
Organizations
Databases
Mortality

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Sampaio, M. S., Molnar, M. Z., Kovesdy, C., Mehrotra, R., Mucsi, I., Sim, J. J., ... Kalantar-Zadeh, K. (2011). Association of pretransplant serum phosphorus with posttransplant outcomes. Clinical Journal of the American Society of Nephrology, 6(11), 2712-2721. https://doi.org/10.2215/CJN.06190611

Association of pretransplant serum phosphorus with posttransplant outcomes. / Sampaio, Marcelo S.; Molnar, Miklos Z.; Kovesdy, Csaba; Mehrotra, Rajnish; Mucsi, Istvan; Sim, John J.; Krishnan, Mahesh; Nissenson, Allen R.; Kalantar-Zadeh, Kamyar.

In: Clinical Journal of the American Society of Nephrology, Vol. 6, No. 11, 01.11.2011, p. 2712-2721.

Research output: Contribution to journalArticle

Sampaio, MS, Molnar, MZ, Kovesdy, C, Mehrotra, R, Mucsi, I, Sim, JJ, Krishnan, M, Nissenson, AR & Kalantar-Zadeh, K 2011, 'Association of pretransplant serum phosphorus with posttransplant outcomes', Clinical Journal of the American Society of Nephrology, vol. 6, no. 11, pp. 2712-2721. https://doi.org/10.2215/CJN.06190611
Sampaio, Marcelo S. ; Molnar, Miklos Z. ; Kovesdy, Csaba ; Mehrotra, Rajnish ; Mucsi, Istvan ; Sim, John J. ; Krishnan, Mahesh ; Nissenson, Allen R. ; Kalantar-Zadeh, Kamyar. / Association of pretransplant serum phosphorus with posttransplant outcomes. In: Clinical Journal of the American Society of Nephrology. 2011 ; Vol. 6, No. 11. pp. 2712-2721.
@article{716c4678b9424e699bb0585abbbcd109,
title = "Association of pretransplant serum phosphorus with posttransplant outcomes",
abstract = "Background and objectives Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. Design, setting, participants, & measurements Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita). The selected 9384 primary kidney recipients were divided into five groups according to pretransplant serum phosphorus levels (mg/dl): <3.5, 3.5 to <5.5 (reference group), 5.5 to <7.5, 7.5 to <9.5, and ≥ 9.5. Unadjusted and multivariate adjusted risks for transplant outcomes were compared. Results Patients were 48±14 years old and included 37{\%} women and 27{\%} African Americans. After multivariate adjustment, all-cause and cardiovascular death hazard ratios were 2.44 (95{\%} confidence interval: 1.28 to 4.65) and 3.63 (1.13 to 11.64), respectively, in recipients in the ≥9.5 group; allograft loss hazard ratios were 1.42 (1.04 to 1.95) and 2.36 (1.33 to 4.17) in recipients with 7.5 to > 9.5 and ≥ 9.5, respectively. No significant association with delayed graft function was found. Conclusions Pretransplant phosphorus levels 7.5 to > 9.5 mg/dl and ≥ 9.5 mg/dl were associated with increased risk of functional graft failure and increased risk of all-cause and cardiovascular deaths, respectively, when compared with 3.5 to < 5.5 mg/dl. Additional studies are needed to examine whether more aggressive control of pretransplant serum phosphorus may improve posttransplant outcomes.",
author = "Sampaio, {Marcelo S.} and Molnar, {Miklos Z.} and Csaba Kovesdy and Rajnish Mehrotra and Istvan Mucsi and Sim, {John J.} and Mahesh Krishnan and Nissenson, {Allen R.} and Kamyar Kalantar-Zadeh",
year = "2011",
month = "11",
day = "1",
doi = "10.2215/CJN.06190611",
language = "English (US)",
volume = "6",
pages = "2712--2721",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - Association of pretransplant serum phosphorus with posttransplant outcomes

AU - Sampaio, Marcelo S.

AU - Molnar, Miklos Z.

AU - Kovesdy, Csaba

AU - Mehrotra, Rajnish

AU - Mucsi, Istvan

AU - Sim, John J.

AU - Krishnan, Mahesh

AU - Nissenson, Allen R.

AU - Kalantar-Zadeh, Kamyar

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background and objectives Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. Design, setting, participants, & measurements Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita). The selected 9384 primary kidney recipients were divided into five groups according to pretransplant serum phosphorus levels (mg/dl): <3.5, 3.5 to <5.5 (reference group), 5.5 to <7.5, 7.5 to <9.5, and ≥ 9.5. Unadjusted and multivariate adjusted risks for transplant outcomes were compared. Results Patients were 48±14 years old and included 37% women and 27% African Americans. After multivariate adjustment, all-cause and cardiovascular death hazard ratios were 2.44 (95% confidence interval: 1.28 to 4.65) and 3.63 (1.13 to 11.64), respectively, in recipients in the ≥9.5 group; allograft loss hazard ratios were 1.42 (1.04 to 1.95) and 2.36 (1.33 to 4.17) in recipients with 7.5 to > 9.5 and ≥ 9.5, respectively. No significant association with delayed graft function was found. Conclusions Pretransplant phosphorus levels 7.5 to > 9.5 mg/dl and ≥ 9.5 mg/dl were associated with increased risk of functional graft failure and increased risk of all-cause and cardiovascular deaths, respectively, when compared with 3.5 to < 5.5 mg/dl. Additional studies are needed to examine whether more aggressive control of pretransplant serum phosphorus may improve posttransplant outcomes.

AB - Background and objectives Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. Design, setting, participants, & measurements Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita). The selected 9384 primary kidney recipients were divided into five groups according to pretransplant serum phosphorus levels (mg/dl): <3.5, 3.5 to <5.5 (reference group), 5.5 to <7.5, 7.5 to <9.5, and ≥ 9.5. Unadjusted and multivariate adjusted risks for transplant outcomes were compared. Results Patients were 48±14 years old and included 37% women and 27% African Americans. After multivariate adjustment, all-cause and cardiovascular death hazard ratios were 2.44 (95% confidence interval: 1.28 to 4.65) and 3.63 (1.13 to 11.64), respectively, in recipients in the ≥9.5 group; allograft loss hazard ratios were 1.42 (1.04 to 1.95) and 2.36 (1.33 to 4.17) in recipients with 7.5 to > 9.5 and ≥ 9.5, respectively. No significant association with delayed graft function was found. Conclusions Pretransplant phosphorus levels 7.5 to > 9.5 mg/dl and ≥ 9.5 mg/dl were associated with increased risk of functional graft failure and increased risk of all-cause and cardiovascular deaths, respectively, when compared with 3.5 to < 5.5 mg/dl. Additional studies are needed to examine whether more aggressive control of pretransplant serum phosphorus may improve posttransplant outcomes.

UR - http://www.scopus.com/inward/record.url?scp=80655139675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80655139675&partnerID=8YFLogxK

U2 - 10.2215/CJN.06190611

DO - 10.2215/CJN.06190611

M3 - Article

VL - 6

SP - 2712

EP - 2721

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 11

ER -